List of Excipients in Branded Drug VARIZIG

VARIZIG Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

VARIZIG is a plasma-derived varicella zoster immune globulin for intramuscular administration. Its commercial value depends less on conventional small-molecule patent exclusivity than on plasma sourcing, donor screening, high-titer antibody production, viral-clearance validation, manufacturing capacity, regulatory compliance, and hospital-channel access. The primary excipient opportunity is formulation optimization around protein stability, injection volume, cold-chain performance, and supply economics.

What is VARIZIG and how is it regulated?

VARIZIG contains human immunoglobulin with antibodies against varicella zoster virus. The FDA approved it for post-exposure prophylaxis in individuals for whom varicella vaccination is contraindicated or unavailable and who are at high risk for severe disease.[1]

VARIZIG is administered intramuscularly. The approved product is supplied in presentations containing 125 international units and 625 international units. Dosing is weight-based, with administration recommended as soon as possible after exposure.[1]

VARIZIG regulatory profile

Attribute	Publicly reported status
Product	VARIZIG
Active substance	Varicella zoster immune globulin human
Dosage form	Intramuscular injection
Regulatory pathway	Biologics license application
FDA approval	2012
Current commercial sponsor identified in labeling	Saol Therapeutics Inc.
Manufacturer identified in labeling	Emergent BioSolutions Canada Inc.
Orange Book status	Not applicable as a biologic licensed under the Public Health Service Act
Relevant FDA reference	Package insert and biologics licensing records
Biosimilar pathway	Potentially relevant under section 351(k), but commercial substitution is not automatic

VARIZIG is not an ordinary generic-drug opportunity. A competing product would need to address biologic comparability, antibody potency, donor-derived variability, viral safety, manufacturing controls, and FDA licensing requirements.

What excipients are used in VARIZIG?

The public product information identifies glycine as a formulation stabilizer and states that the product contains no preservative.[1] VARIZIG is a protein solution derived from human plasma. The principal formulation challenge is maintaining immunoglobulin integrity during processing, storage, transport, and intramuscular injection.

The label describes a low-pH immunoglobulin formulation and identifies glycine as an excipient. Public labeling should be treated as the controlling source for the currently marketed formulation because excipient composition can change through approved manufacturing supplements.

Publicly relevant formulation characteristics

Formulation factor	Commercial significance
Glycine stabilization	Supports immunoglobulin stability during storage
No preservative	Reduces preservative-related tolerability concerns but limits multidose-container options
Human plasma-derived protein	Creates requirements for donor qualification, pathogen testing, fractionation, and viral clearance
Intramuscular route	Favors low injection volume, manageable viscosity, and local tolerability
Refrigerated storage	Creates cold-chain and inventory-management requirements
High-titer antibody content	Determines potency, plasma sourcing economics, and batch consistency
Single-use presentation	Reduces contamination risk but increases packaging and wastage considerations

Potential formulation work must preserve antibody activity and avoid changes in aggregation, fragmentation, turbidity, pH, osmolality, and viscosity. A new excipient is commercially valuable only if it produces a measurable advantage without creating new clinical, toxicological, or comparability burdens.

What excipient strategies could improve VARIZIG?

The highest-value strategy is a platform approach that improves stability while preserving the existing intramuscular route. The relevant objectives are longer refrigerated shelf life, reduced sensitivity to temperature excursions, reduced aggregation, lower injection pain, and more efficient fill-finish.

1. Alternative amino-acid stabilization

Glycine is established in immunoglobulin products and has a favorable regulatory history. A reformulation could evaluate other amino acids or amino-acid combinations, including proline, histidine, or arginine, subject to compatibility and toxicological review.

The commercial case would require evidence of one or more of the following:

• Lower aggregate formation during accelerated stability testing
• Improved retention of anti-varicella potency
• Better recovery after freeze-thaw or shipping excursions
• Reduced viscosity at the target protein concentration
• Longer shelf life at refrigerated conditions

A simple substitution of glycine would have limited commercial value unless it creates a measurable stability or manufacturing benefit. The strongest position would combine a new stabilizer system with data demonstrating improved product performance.

2. Surfactant-based protection

Low concentrations of nonionic surfactants can reduce protein adsorption to glass, rubber closures, and manufacturing equipment. They may also reduce interfacial stress during filling and transport.

For VARIZIG, this strategy would require particular attention to:

• Compatibility with plasma-derived immunoglobulin
• Extractables and leachables
• Peroxide formation
• Container-closure interaction
• Effects on intramuscular tolerability
• Stability of the surfactant over the proposed shelf life

Surfactants can improve robustness but can also introduce degradation pathways. They should be evaluated as part of a defined container-closure and process-control strategy rather than as an isolated excipient change.

3. Buffer and pH optimization

The product’s acidic formulation supports protein stability and microbial control. A reformulation could evaluate citrate, acetate, phosphate, histidine, or mixed-buffer systems, but the acceptable pH range would be constrained by immunoglobulin stability and intramuscular tolerability.

A buffer patent would be strongest if it claimed a narrow composition range tied to unexpected performance, such as:

• Reduced dimer or aggregate growth
• Preserved antibody binding after thermal stress
• Lower subvisible particle formation
• Improved fill-finish yield
• Reduced injection-site reactions

Broad claims covering any immunoglobulin buffer would face greater validity and freedom-to-operate risk because similar systems are widely disclosed in the immunoglobulin field.

4. Excipient systems for temperature excursion control

VARIZIG is distributed through hospital and public-health channels where refrigerated handling is important. A formulation that tolerates short-term temperature excursions could reduce product loss and improve emergency deployment.

The commercial opportunity is strongest if the product can demonstrate:

• Defined stability at room temperature for emergency use
• Retention of potency after transportation stress
• No increase in aggregates or particles
• Compatibility with existing vial and stopper systems
• No requirement for a new administration device

A temperature-tolerant formulation could support premium pricing, particularly for emergency stockpiles and remote healthcare settings. The claim scope would need to cover the composition and the storage method, not only a general statement that the product is stable.

What patents protect VARIZIG?

Public product information establishes the FDA-approved product and its formulation characteristics, but it does not establish a current, enforceable patent estate covering VARIZIG. Plasma-derived immune globulin products often rely on regulatory, manufacturing, trade-secret, and supply-chain barriers rather than a large Orange Book patent portfolio.

Patent categories relevant to VARIZIG

Patent or IP category	Relevance
Composition patents	May cover a defined antibody concentration, stabilizer, pH, or excipient combination
Method-of-use patents	May cover prophylaxis in defined populations or exposure settings
Manufacturing patents	May cover plasma pooling, fractionation, purification, viral inactivation, or concentration
Analytical patents	May cover potency, titer, impurity, or aggregation testing
Container-closure patents	May cover vial, stopper, syringe, or low-adsorption packaging
Trade secrets	Often critical for donor qualification, plasma selection, process parameters, and yield
Regulatory exclusivity	Depends on the biologic license and applicable FDA exclusivity period
Trademark rights	Protect the VARIZIG brand but do not block a competing licensed product

No Orange Book-listed patents should be assumed for VARIZIG because the product is a biologic rather than a conventional drug approved under an NDA. Patent and exclusivity analysis should instead examine the biologics license, FDA reference-product status, Purple Book information where applicable, issued patents assigned to the sponsor or manufacturer, and licensing or manufacturing agreements.

When does VARIZIG lose exclusivity?

VARIZIG’s commercial exclusivity is not defined by a single Orange Book expiration date. For a reference biologic, the relevant statutory framework includes the FDA’s 12-year reference-product exclusivity period under the Biologics Price Competition and Innovation Act, subject to the applicable approval and reference-product rules.[2]

Because VARIZIG was approved in 2012, the statutory reference-product exclusivity period would generally have elapsed. That does not mean an immediate generic-style launch. A competing manufacturer would still need FDA authorization, adequate clinical and analytical support, a compliant plasma supply, and manufacturing capacity.

Practical loss-of-exclusivity timeline

Event	Commercial effect
FDA biologics approval	Establishes the reference product
Expiration of statutory reference exclusivity	Opens the section 351(k) biosimilar pathway, subject to statutory requirements
Patent expiration or invalidation	Removes a separate legal barrier if valid patents exist
Manufacturing scale-up	Determines whether a competitor can supply hospitals
Payer and channel adoption	Determines the speed of commercial erosion
Hospital formulary conversion	May be slower than for ordinary injectables because of supply and clinical familiarity

A competitor could also pursue a standalone biologics license under section 351(a), avoiding reliance on biosimilar interchangeability but accepting a more extensive development and regulatory burden.

Are there Paragraph IV challenges to VARIZIG?

Paragraph IV litigation applies to patents listed in the Orange Book for NDA products. VARIZIG is regulated as a biologic, so a conventional Paragraph IV filing is not the expected challenge mechanism.

A competitor would more likely pursue one of three routes:

1. A biosimilar application under section 351(k)
2. A standalone biologics license under section 351(a)
3. A patent challenge through declaratory judgment, infringement litigation, or post-grant proceedings if relevant patents are asserted

The absence of a conventional Paragraph IV pathway reduces the likelihood of an early, standardized generic launch process. It does not eliminate patent risk. Manufacturing, formulation, use, and process patents can still create litigation exposure.

What formulation patents could be developed around VARIZIG?

The strongest patent strategy would focus on technically narrow, data-supported claims. Potential claim clusters include:

Stabilized varicella zoster immune globulin

Claims could cover a defined immunoglobulin concentration, glycine or mixed-excipient concentration, pH range, aggregate limit, and potency threshold.

Temperature-stable formulations

Claims could cover a composition that maintains anti-varicella activity after specified temperature excursions or storage periods.

Low-volume intramuscular formulations

Claims could cover increased antibody concentration while controlling viscosity, osmolality, and injection-site tolerability.

Reduced-aggregate formulations

Claims could cover excipient combinations or process conditions that limit high-molecular-weight species and subvisible particles.

Container-closure systems

Claims could cover low-adsorption vial materials, elastomer compositions, or packaging that preserves immunoglobulin potency.

Manufacturing methods

Claims could cover plasma selection based on anti-varicella titer, fractionation conditions, purification steps, viral inactivation, or concentration methods.

Patent strength would depend on unexpected results. Generic claims to "an immunoglobulin formulation containing an amino acid" would face substantial prior-art exposure. Narrow claims linked to VARIZIG’s antibody titer, stability profile, and intramuscular performance would provide stronger differentiation.

What commercial opportunities exist for VARIZIG excipients?

Reformulation licensing

An excipient developer could license a stabilizer or container-closure technology to the product sponsor or manufacturer. The most attractive deal structure would combine:

• Upfront payment for formulation access
• Development milestones
• Regulatory milestones
• Supply rights for the excipient
• Royalties on net sales
• Field-of-use restrictions covering varicella zoster immune globulin

Private-label and regional supply

A reformulated product could support private-label distribution through hospital wholesalers, specialty distributors, government procurement programs, or regional public-health agencies. The constraint is that the product would need its own FDA-approved manufacturing and regulatory pathway unless the change is implemented through an approved supplement.

Emergency stockpiles

VARIZIG is relevant to post-exposure prophylaxis in vulnerable populations, including certain immunocompromised patients, pregnant individuals, newborns, and premature infants.[1] Products with better temperature-excursion tolerance or longer shelf life could reduce stockpile wastage.

International market expansion

The United States is only one market for varicella zoster immune globulin. Opportunities exist in jurisdictions where:

• Varicella vaccination coverage is incomplete
• Immunoglobulin supply is imported
• National stockpiles are used for vulnerable populations
• Local plasma fractionation capacity is limited

Geographic expansion requires country-specific biologic licensing, plasma rules, pharmacovigilance, labeling, and cold-chain compliance.

Manufacturing yield improvement

A process that increases recovery of high-titer antibody from each plasma pool could create more value than a marginal excipient change. Yield improvement reduces dependence on rare high-titer donors, lowers cost per dose, and supports larger government or hospital contracts.

How strong is the VARIZIG competitive position?

VARIZIG’s main barriers are operational rather than classic patent barriers.

Barrier	Relative importance
High-titer plasma supply	Very high
Donor screening and pathogen safety	Very high
Validated fractionation and viral clearance	Very high
FDA biologics manufacturing compliance	Very high
Clinical familiarity and hospital access	High
Brand recognition	Moderate
Formulation patent protection	Unclear from public product information
Orange Book protection	Not applicable
Biosimilar substitution	Potentially limited without interchangeability designation
Cold-chain logistics	High

A new entrant would face a difficult supply-chain buildout even if patent barriers were weak. This favors partnerships with established plasma fractionators, contract manufacturers, or blood-product distributors.

What litigation and settlement risks affect VARIZIG?

No conventional Orange Book Paragraph IV litigation framework should be assumed. Potential disputes would center on:

• Manufacturing-process patents
• Formulation patents
• Antibody potency or purification methods
• Trade-secret misappropriation
• Supply and licensing agreements
• Trademark and product-labeling rights
• Biosimilar patent-disclosure and litigation procedures

Settlement agreements could involve delayed entry, manufacturing licenses, regional commercialization rights, or cross-licenses. Publicly disclosed settlement terms should be reviewed before relying on any exclusivity date or launch forecast.

Key Takeaways

• VARIZIG is a plasma-derived varicella zoster immune globulin regulated as a biologic.
• Glycine is identified in public labeling as a stabilizer, and the product contains no preservative.[1]
• The commercial opportunity is strongest in stability, temperature-excursion tolerance, low-volume delivery, container closure, and manufacturing yield.
• VARIZIG does not fit the conventional Orange Book or Paragraph IV generic model.
• Statutory biologic reference-product exclusivity associated with a 2012 approval would generally have elapsed, but regulatory and manufacturing barriers remain significant.
• The most defensible new patents would claim narrow excipient combinations, stability results, concentration ranges, container systems, or manufacturing processes.
• Plasma sourcing and viral-safety infrastructure are likely more important competitive barriers than brand or formulation patents.
• Potential partners include plasma fractionators, biologic contract manufacturers, excipient developers, government suppliers, and specialty distributors.

FAQs

Can a generic drug company launch a generic version of VARIZIG?

No conventional ANDA generic route should be assumed. A competitor would generally need a biosimilar application under section 351(k) or an independent biologics license under section 351(a).

Is VARIZIG listed in the FDA Orange Book?

No. Orange Book listing is associated primarily with NDA products. VARIZIG is a biologic licensed under the Public Health Service Act.

Could a new excipient create patent protection for VARIZIG?

Yes, but the strongest claims would require a defined formulation and demonstrated technical effect, such as improved potency retention, lower aggregation, or better temperature stability.

What is the main supply risk for VARIZIG?

The primary supply risk is access to plasma with sufficiently high varicella zoster antibody titers, followed by validated fractionation, viral-clearance capacity, and compliant fill-finish operations.

Would a temperature-stable VARIZIG formulation command a premium?

It could, particularly for emergency stockpiles and distribution channels with unreliable refrigeration. The premium would depend on validated stability data, reduced wastage, procurement contracts, and regulatory approval.

References

1. Saol Therapeutics Inc. (n.d.). VARIZIG: Varicella zoster immune globulin (human) injection prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (2023). Implementation of the Biologics Price Competition and Innovation Act of 2009. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/implementation-biologics-price-competition-and-innovation-act-2009